Looks at treatments and HER2 and PD-L1 markers in bladder cancer
Observes how bladder cancer patients are treated and how often markers are present.
Plain-language title generated from the registry record
Registry title: TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Key facts
- Where
- Arkhangelsk, Barnaul, Chelyabinsk, Krasnodar, Krasnoyarsk, Makhachkala, Moscow, Nizhny Novgorod, Novosibirsk, Obninsk, Omsk, Saint Petersburg, Tomsk, Tyumen, Ufa, and Yekaterinburg, RussiaSee the 16 sites
Where in Russia
- ArkhangelskArkhangelsk, RussiaTaking people
- BarnaulBarnaul, RussiaTaking people
- ChelyabinskChelyabinsk, RussiaTaking people
- KrasnodarKrasnodar, RussiaTaking people
- KrasnoyarskKrasnoyarsk, RussiaTaking people
- MakhachkalaMakhachkala, RussiaTaking people
- MoscowMoscow, RussiaTaking people
- Nizhny NovgorodNizhny Novgorod, RussiaTaking people
- NovosibirskNovosibirsk, RussiaNo longer taking part
- ObninskObninsk, RussiaNot yet recruiting
- OmskOmsk, RussiaTaking people
- Saint PetersburgSaint Petersburg, RussiaTaking people
- TomskTomsk, RussiaTaking people
- TyumenTyumen, RussiaTaking people
- UfaUfa, RussiaTaking people
- YekaterinburgYekaterinburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07038928
- Record updated
- 14 September 2026
- Original description
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian FederationRead full original descriptionShow less
A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Inclusion: Age ≥ 18 years; Signed ICF, including consent for FFPE tumor tissue sample testing; Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry; For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:; T1 tumor; High grade/G3 tumor; CIS (carcinoma in situ); Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point); For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry; For patients with mBC: mBC diagnosed during 12 months prior to study entry; Availability of medical history data; Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.
Exclusion: Participation in any interventional trial since the urothelial bladder cancer diagnosis.